An inactivated novel chimeric FAdV-4 containing fiber of FAdV-8b provides full protection against hepatitis-hydropericardium syndrome and inclusion body hepatitis

• Published in: Veterinary research (Paris) Vol. 53; no. 1; pp. 1 - 75
• Main Authors: Wang, Baiyu, Song, Mingzhen, Song, Congcong, Zhao, Shiyi, Yang, Panpan, Qiao, Qilong, Cong, Yanfang, Wang, Yanling, Wang, Zeng, Zhao, Jun
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 30.09.2022; BioMed Central; BMC
• Subjects: Adenoviruses; Antibodies; Binding sites; bivalent vaccine; Cloning; DNA polymerase; E coli; Fowl adenovirus serotype 4; fowl adenovirus serotype 8b; Health aspects; Hepatitis; hepatitis-hydropericardium syndrome; inclusion body hepatitis; Infection; Infections; Parenting; Pathogenesis; Poultry; Prevention; Scientific equipment and supplies industry; Vaccines; Viral antibodies; Viral infections; Virus diseases; Viruses; United States; China; Beijing China; Australia; United States > US
• ISSN: 1297-9716; 0928-4249; 1297-9716
• DOI: 10.1186/s13567-022-01093-2

Fowl adenovirus serotype 4 (FAdV-4) and FAdV-8b are causative agents of hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH), respectively. HHS and IBH co-infections were often reported in clinical, yet there are no commercially available bivalent vaccines for prevention and control of both FAdV-4 and -8b. In the present study, a chimeric FAdV-4 was firstly generated by substituting fiber-1 of FAdV-4 with fiber of FAdV-8b. The chimeric virus, rFAdV-4-fiber/8b, exhibited similar replication ability in vitro and pathogenicity in vivo to the parental wild type FAdV-4. A single dosage of vaccination with the inactivated rFAdV-4-fiber/8b induced high antibody titers against fiber-2 of FAdV-4 and fiber of FAdV-8b and provided full protection against FAdV-4 and -8b challenge. These results demonstrated that fiber of FAdV-8b could replace the role of fiber-1 of FAdV-4 in the process of viral infection, and rFAdV-4-fiber/8b could be used to make a potential bivalent vaccine for the control and prevention of HHS and IBH.